Table 2 BMD data at baseline, 6- and 12-months. Comparison of BMD at baseline and its changes at 6- and 12-months in patients with established osteoporosis compared between Alendronate group and placebo control group (Data: mean ± SD)

Baseline

6-month

12-month

% difference ⁺

Baseline

6-month

12-month

% difference ⁺

Spine (L2-L4)

0.718 ± 0.101

0.709 ± 0.105

0.710 ± 0.102

-0.7 ± 3.3

0.719 ± 0.097

0.743 ± 0.101 *

0.756 ± 0.094 **

5.1 ± 4.2 ^a

Femoral Neck

0.631 ± 0.060

0.633 ± 0.053

0.632 ± 0.055

-0.1 ± 4.1

0.653 ± 0.121

0.658 ± 0.129

0.670 ± 0.129 **

2.5 ± 3.2 ^b

tBMD

138.6 ± 29.3

135.3 ± 31.5

137.3 ± 31.9

-0.6 ± 6.4

126.8 ± 46.4

130.4 ± 44.3 *

130.8 ± 44.5 *

0.9 ± 5.1

iBMD

424.5 ± 73.0

421.0 ± 75.6

429.9 ± 82.3

0.1 ± 3.2

388.1 ± 79.4

383.4 ± 79.6

385.4 ± 91.0

0.2 ± 3.8

cBMD

1124.2 ± 172.9

1070.7 ± 289.3

1113.0 ± 178.4 **

-1.4 ± 2.2

1084.3 ± 202.8

1024.7 ± 329.8

1077.6 ± 203.3

0.1 ± 2.4 ^b